Management of patients with early-stage triple-negative breast cancer following pembrolizumab-based neoadjuvant therapy: What are the evidences?
Renata Colombo Bonadio, Paolo Tarantino, Laura Testa, Kevin Punie, Sònia Pernas, Carlos H. Barrios, Giuseppe Curigliano, Sara M. Tolaney, Romualdo Barroso‐Sousa
Topics & Concepts
MedicinePembrolizumabCapecitabineOncologyNeoadjuvant therapyBreast cancerInternal medicineAdjuvantAdjuvant therapyTriple-negative breast cancerChemotherapyCancerImmunotherapyColorectal cancerPARP inhibition in cancer therapyCancer Immunotherapy and BiomarkersAdvanced Breast Cancer Therapies